Answers are grounded in this paper and cite their sources.
Combination treatment with eprenetapopt and azacitidine is well-tolerated yielding high rates of clinical response and molecular remissions in patients with TP53-mutant MDS and oligoblastic AML.
No takes yet. Share an insight, caveat, or question.
Sallman et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: